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ABSTRACT
There has been a recent upsurge in prevalence of dia-
betes mellitus in developing world. This has resulted in 
exponential increase in the incidence of both commu-
nicable and non-communicable diseases. Some of the 
infections increase morbidity and mortality associated 
with diabetes. Rhino-orbital-cerebral mucormycosis 
(ROCM) is one of the fatal opportunistic infections in 
diabetes. There is little data published regarding the 
short and long term management of patients suffering 
from this invasive fungal infection. Hereby, we report 
few cases of ROCM with varied presentations and 
their short and long term follow up. These patients 
were initially treated with injectable amphotericin B 
and later followed up with oral posaconazole. (Clin 
Diabetol 2020; 9)
Key words: diabetes, posaconazole, rhino-orbital- 
-cerebral mucormycosis
Introduction
As incidence of diabetes is rising globally, infec-
tions and sepsis are also imposing enormous burden 
on the disease outcome [1]. Mucormycosis is relatively 
uncommon and frequently fatal angio-invasive fungal 
infection. It usually develops in immunocompromised 
patients and diabetes is a common predisposing fac-
tor [2]. Despite aggressive surgical debridement and 
antifungal therapy, the prognosis of disease is markedly 
poor. Antifungal agents have poor tissue penetration 
property so surgical intervention should be considered 
first for the treatment of invasive fungal infection. Due 
to need for extensive surgical debridement, role of 
other treatment modalities should be explored. Here, 
we describe three patients with ROCM with varied 
clinical stages, treated with conventional therapy i.e. 
amphotericin B later posaconazole was started for 
follow up.
Case report
A 50 year old male patient who had uncontrolled 
type 2 diabetes mellitus for one and a half years pre-
sented with high fever for 10 days along with pain 
and swelling in left side of face and eye. Later, patient 
developed diplopia and unilateral decrease in vision 
for five days followed by complete loss of vision for 
last two days. It was accompanied by difficulty in 
swallowing specially for solids, non bilious vomiting 
and change in voice. General physical examination 
was normal. At the time of examination, patient was 
conscious with oral temperature of 39.8°C, a blood 
pressure of 140/90 mm Hg and a pulse of 116/min. Vi-
sion and ocular movements in the right eye was normal 
but the left eye showed negative perception of light. 
Pupils were fixed and dilated. Ophthalmoplegia was 
present. Movements were restricted in all directions. 
Initial assessment showed leucocytosis with raised ESR 
and slightly decreaased kidney function test. The initial 
HbA1c was 13.6% on oral hypoglycemic regimen. Chest 
X ray was normal. ENT examination showed blackish 
Address for correspondence:  
Dr SV Madhu
Centre for Diabetes Endocrinology and Metabolism
University College of Medical Sciences and GTB Hospital
Dilshad Garden, Delhi-110095, India
Phone:+91-11-22596438
e-mail: drsvmadhu@gmail.com
Clinical Diabetology 2020, 9
DOI: 10.5603/DK.2020.0005
Received: 30.10.2019  Accepted: 26.12.2019
Clinical Diabetology 2020, Vol. 9
2
ulcerating growth in middle meatus. Potassium hy-
droxide mount (KOH) proved mucormycosis and later 
contrast enhanced MRI revealed left rhino-orbito-cere-
bral mucormycosis with cavernous sinus thrombosis. 
Involvement of left sided ethmoid, maxillary and frontal 
sinus was also present. There was intraorbital extension 
into medial orbit, medial rectus, orbital apex, inferior 
orbital fissure with slight extension into infratemporal 
fossa. Left cavernous sinus appeared bulky. Patient was 
started on liposomal amphotericin B along with broad 
spectrum antibiotics. Diabetes was controlled with 
multi dosage insulin regimen (on a dose of approx 0.9 
units per kg body weight). Amphotericin B was started 
at a dose of 3 mg/kg which was escalated to 5 mg/kg 
and continued for 6 weeks. No surgical intervention was 
done. Repeated ENT and ophthalmological consultation 
was sought. Repeat MRI was done after 6 weeks of 
injectable therapy that showed no further progression 
although there was reduced bulkiness in the cavernous 
sinus. Clinically, ophthlmoplegia and restriction of eye 
ball movement completely recovered with slight im-
provement in vision over the time. Patient was put on 
oral posaconazole therapy at a dose of 800 mg per day 
and 4 months down the line, patient showed clinical 
improvement with no signs of radiological worsening.
Another patient, 50 years old diabetic female 
presented with painful swelling in the left retro-orbital 
region and nose for five days along with fever and pro-
gressive breathing difficulty. On admission, the patient 
was conscious with oral temperature of 39.4°C, a blood 
pressure of 120/80 mm Hg and a pulse of 130/min. She 
was unable to open the left eye and her vision and left 
pupillary light reflex were lost. There was leucocytosis, 
ketonemia with normal liver function, renal function 
and electrolytes. Blood gasometry confirmed metabolic 
acidosis. The initial HbA1c was 12.9%. Patient was man-
aged as per diabetic ketoacidosis (DKA) protocol and 
ENT consultation was sought which was suggestive of 
extensive black necrotic tissue in the nasal cavity. The 
patient’s nasal structure was completely destroyed 
and the hard palate was perforated. KOH mount was 
suggestive of mucormycosis. Patient was started on 
liposomal amphotericin B along with broad spectrum 
antibiotics. Liposomal amphotericin B was started at a 
dose of 3 mg/kg which was escalated to 5 mg/kg and 
continued for 8 weeks. Diabetes was initially controlled 
with multi dosage insulin regimen (on a dose of approx 
1.2 units per kg body weight) and later stabilized on 
approx 0.75 units per kg body weight. Extensive surgi-
cal debridement was done. Patient improved clinically 
and was discharged with no active residual apparent 
disease. On follow up, her clinical status remained fair. 
However, this patient died in the emergency room due 
to severe pneumonia, respiratory distress with septic 
shock after one and half years.
The third patient, a 50 years old female with type 2 
diabetes for 10 years presented with painful swelling 
of the right side of face and right eye for one and 
a half months. On admission, the patient was conscious 
with oral temperature of 39.4°C, a blood pressure of 
130/80 mm Hg and a pulse of 100/min. She was unable 
to open the right eye although vision and right pupillary 
light reflex were normal. There was leucocytosis with 
normal liver function, renal function and electrolytes. 
The initial HbA1c was 13.4%. ENT consultation was 
sought that showed extensive fungal sinus invasion. 
She was started on basal bolus insulin regimen at 
a dose of 0.5 units per kilogram body weight but 
control was finally achieved on 0.7 units per kilogram 
body weight. Liposomal amphotericin B was started 
at a dose of 3 mg/kg which was escalated to 5 mg/kg 
and continued for 6 weeks. Surgery was deferred due to 
extensive intracerebral involvement. As per ENT opinion 
patient had been put on amphotericin nasal douche. 
Later, patient was put on oral posaconazole therapy at 
a dose of 800 mg per day.
Discussion
Mucormycosis is a fatal opportunistic infec-
tion caused by fungi Mucorales, Rhizopus, Mucor 
and Rhizomucor species. It usually affects immune-
compromised or immune suppressed patients [3]. Till 
date, surgical debridement is the gold standard for the 
treatment of ROCM. Surgical debridement has its own 
limitations. There are several issues in the management 
of ROCM which still remain unclear. Firstly, most of 
the recommendations advocate surgical debridement 
as important lifesaving procedure [4]. This option is 
often limited due to various reasons (extensive and 
disfiguring surgery). Secondly, there is no consensus 
about the duration of the amphotericin B treatment 
despite unanimity that this is always the first line of 
treatment. There is not enough data to clarify its dura-
tion of use and appropriate time of stopping the treat-
ment. Most recommendations mention amphotericin B 
should be given till there is radiological and clinical 
improvement [4]. However, it is often seen in clinical 
practice that radiological recovery beyond a point is 
minimal and slow in the absence of surgical debride-
ment. This makes it difficult to decide precisely when 
to stop amphotericin B.
We gave amphotericin B for 6–10 weeks after diag-
nosis of the patients which was followed by clinical im-
provement with some radiological recovery (definitely 
Nishesh Jain, Sri Venkata Madhu, Management of rhino-orbito-cerebral mucormycosis
3
no worsening). Long term follow up treatment with oral 
posaconazole or other oral antifungal agents follow-
ing long use of injectable AMB is not indicated. Yet we 
tried oral posaconazole in two patients for six to eight 
weeks. Now the patients are clinically improved with 
no definite radiological worsening. This suggests that 
posaconazole may be useful as a step down therapy 
after initial amphotericin B treatment. This case report 
suggests that opportunistic infections are commonly 
associated with poorly controlled diabetes. Rhino-
-orbito-cerebral mucormycosis appear to be one of 
the primary infection among opportunistic infections.
 So, the alternative efficacious therapies are be-
ing explored. A few experimental reports have shown 
promising results with posaconazole or ravuconazole 
but clinical data shows little or no effect [5]. According 
to a case report, posaconazole with amphotericin B has 
shown some promising result [6]. In addition to posa-
conazole, isavuconazole has been approved by FDA [7]. 
Conclusion 
This data supports the essential and alternative 
treatment modalities for the treatment of rhino-orbito-
-cerebral mucormycosis. Oral antifungal agents e.g., 
posaconazole appears to have promising role as add 
on therapy in treatment of ROCM.
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